Anitrazafen (LY 122512)
(Synonyms: 阿尼扎芬; LY 122512) 目录号 : GC31859
Annitrazafen (LY 122512) 是一种局部有效的抗炎剂。
Cas No.:63119-27-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Anitrazafen is a topically effective antiinflammatory agent.
Anitrazafen is a topically effective antiinflammatory agent. The disposition of 14C in normal and in bile-duct cannulated rats after oral administration of a single dose of 25 mg/kg of [3-14C]Anitrazafen shows the drug to be well absorbed from the gastro-intestinal tract and biliary excretion to be the major route of elimination of drug and/or metabolites. Plasma concentrations of total 14C after subcutaneous administration of [3-14C]Anitrazafen in corn oil solution are about one half those found after oral administration[1].
[1]. Sullivan HR, et al. Absorption and metabolism of anitrazafen, a topically effective anti-inflammatory agent, in the rat. Xenobiotica. 1981 Jan;11(1):9-22.
Animal experiment: | Male albino rats (200 to 250 g) are fasted for 24 h before experiment. [3-14C]Anitrazafen (25 mg/kg) is administered orally to twelve rats. At specific times after dosing, three animals are killed by decapitation and samples of blood and appropriate tissues are removed. Duplicate weighed samples of blood and each tissue are removed for 14C assay[1]. |
References: [1]. Sullivan HR, et al. Absorption and metabolism of anitrazafen, a topically effective anti-inflammatory agent, in the rat. Xenobiotica. 1981 Jan;11(1):9-22. | |
| Cas No. | 63119-27-7 | SDF | |
| 别名 | 阿尼扎芬; LY 122512 | ||
| Canonical SMILES | CC1=NC(C2=CC=C(OC)C=C2)=C(C3=CC=C(OC)C=C3)N=N1 | ||
| 分子式 | C18H17N3O2 | 分子量 | 307.35 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2536 mL | 16.2681 mL | 32.5362 mL |
| 5 mM | 0.6507 mL | 3.2536 mL | 6.5072 mL |
| 10 mM | 0.3254 mL | 1.6268 mL | 3.2536 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet